EcoDrugPlus

Prostaglandin E Receptor 1b (Subtype Ep1)

Ensembl ID : ENSONIG00000008088
Gene Symbol: PTGER1B
1 Cross references
164 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSONIG00000027660
Gene Symbol: PTGER3
3 Cross references
194 Possible Orthologues:

Prostaglandin E2 Receptor Ep1 Subtype

Ensembl ID : ENSONIG00000018911
Gene Symbol: LOC102080433
4 Cross references
167 Possible Orthologues:

Prostaglandin E2 Receptor Ep2 Subtype

Ensembl ID : ENSONIG00000041344
Gene Symbol: LOC100703512
4 Cross references
202 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype

Ensembl ID : ENSONIG00000011266
Gene Symbol: LOC100703727
4 Cross references
201 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype

Ensembl ID : ENSONIG00000036613
Gene Symbol: LOC100705061
4 Cross references
202 Possible Orthologues:

Prostaglandin F Receptor

Ensembl ID : ENSONIG00000002071
Gene Symbol: PTGFR
3 Cross references
195 Possible Orthologues:

Prostaglandin G/h Synthase 1

Ensembl ID : ENSONIG00000010712
Gene Symbol: LOC100699955
3 Cross references
212 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSONIG00000005975
Gene Symbol: PTGIR
3 Cross references
187 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSONIG00000007497
Gene Symbol: PTGS1
1 Cross references
182 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 2b

Ensembl ID : ENSONIG00000010015
Gene Symbol: PTGS2B
1 Cross references
214 Possible Orthologues:

Proteasomal Ubiquitin Receptor Adrm1

Ensembl ID : ENSONIG00000031294
Gene Symbol: LOC100701093
4 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).